Table 5.
Prognostic significance of the expression of glypicans on the relapse-free survival of breast cancer patients stratified by progesterone receptor (PR) status
| Genes | PR Status | Relapse free survival | ||
|---|---|---|---|---|
| Number of cases | HR 95% CI | P value | ||
| GPC1 | Positive | 589 | 1.41 (0.99–2.01) | 0.054 |
| Negative | 549 | 1.6 ( 1.19–2.16) | 0.0017 | |
| GPC2 | Positive | 489 | 1.1 (0.75–1.61) | 0.63 |
| Negative | 372 | 0.98 (0.69–1.4) | 0.92 | |
| GPC3 | Positive | 589 | 0.94 (0.66–1.33) | 0.72 |
| Negative | 549 | 1 (0.75–1.34) | 1 | |
| GPC4 | Positive | 589 | 1.11 (0.78–1.57) | 0.55 |
| Negative | 549 | 1.05 (0.79–1.41) | 0.74 | |
| GPC5 | Positive | 589 | 1.18 (0.83–1.66) | 0.36 |
| Negative | 549 | 0.99 (0.74–1.32) | 0.93 | |
| GPC6 | Positive | 489 | 1.19 (0.81–1.74) | 0.37 |
| Negative | 372 | 1.29 (0.9–1.84) | 0.16 | |
Bold typing of P values indicates a significance level P < 0.05
HR Hazard ratio, CI confidence interval